145 related articles for article (PubMed ID: 32868525)
1. Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsui S; Teramukai S; Murotani K; Ajioka Y; Shimazaki H; Maeda A; Takuma K; Yoshida T; Kambara T; Matsuda K; Takagane A; Tomita N; Sugihara K;
Am J Surg Pathol; 2020 Dec; 44(12):1685-1698. PubMed ID: 32868525
[TBL] [Abstract][Full Text] [Related]
2. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
[TBL] [Abstract][Full Text] [Related]
3. Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.
Konishi T; Shimada Y; Lee LH; Cavalcanti MS; Hsu M; Smith JJ; Nash GM; Temple LK; Guillem JG; Paty PB; Garcia-Aguilar J; Vakiani E; Gonen M; Shia J; Weiser MR
Am J Surg Pathol; 2018 Jun; 42(6):705-714. PubMed ID: 29624511
[TBL] [Abstract][Full Text] [Related]
4. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
5. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
6. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
7. Is Microsatellite Status Associated With Prognosis in Stage II Colon Cancer With High-Risk Features?
Cavallaro PM; Stafford C; Cauley CE; Berger DL; Bordeianou L; Kunitake H; Francone T; Ricciardi R
Dis Colon Rectum; 2021 May; 64(5):545-554. PubMed ID: 33939386
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
9. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters.
Ueno H; Hase K; Hashiguchi Y; Shimazaki H; Tanaka M; Miyake O; Masaki T; Shimada Y; Kinugasa Y; Mori Y; Kishimoto M; Kameoka S; Sato Y; Matsuda K; Nakadoi K; Shinto E; Nakamura T; Sugihara K
Am J Surg Pathol; 2014 Feb; 38(2):197-204. PubMed ID: 24418853
[TBL] [Abstract][Full Text] [Related]
10. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database.
Achilli P; Crippa J; Grass F; Mathis KL; D'Angelo AD; Abd El Aziz MA; Day CN; Harmsen WS; Larson DW
Int J Cancer; 2021 Jan; 148(1):161-169. PubMed ID: 32638371
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial.
Protic M; Stojadinovic A; Nissan A; Wainberg Z; Steele SR; Chen DC; Avital I; Bilchik AJ
J Am Coll Surg; 2015 Sep; 221(3):643-51; quiz 783-5. PubMed ID: 26213360
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
16. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.
Lee VWK; Chan KF
Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008
[TBL] [Abstract][Full Text] [Related]
17. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
[TBL] [Abstract][Full Text] [Related]
19. Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Tashiro J; Yamaguchi S; Ishii T; Suzuki A; Kondo H; Morita Y; Hara K; Koyama I
World J Surg Oncol; 2014 May; 12():145. PubMed ID: 24884880
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
